Abstract
Nori-peptides have a potent angiotensin I converting enzyme (ACE) inhibitory activity. It has been fractionated from red alga porphyrayezoensis(Nori) by using iron-exchange and gel-filtration. Previous report showed that amino acid sequences of ACE inhibitory Nori-peptides were Ile-Tyr, Met-Lys-Tyr, Ala-Lys-Thy-Ser-Thyr, and Leu-Arg-Tyr, and 200mg/kg of Nori-peptides induced a significant blood pressure reduction in spontaneously hypertensive rats (Suetuna K. J Mar Biotechnol 1998; 6:163–167). We examined the efficacy and safety of Nori-peptides in humans. The subjects enrolled in this study were 64 hypertensive patients (36 men and 28 women, 59.9±2.0 years) and 29 normotensive subjects (15 men and 14 women, 51.9±3.6 years). Nori-peptides 1.8g/day was administered and change of blood pressure was followed for 35 days. Nori-peptide induced a significant blood pressure reduction in hypertensive patients (157.9±14.4/95.1±11.1 to 142.3±16.0/86.8±10.2 mmHg, p<0.001), but did not showed a significant depressor effect in normotensive Subjects (121.1±10.5/80.2 to 118.0 ±15.0/76.6±9.4 mmHg). There was no significant changes in clinical laboratory findings included blood count, serum creatinine, electrolyte, liver function test or blood glucose. It can be concluded that Nori-peptides have a significant antihypertensive effect in hypertensive patients as well as spontaneously hypertensive rats.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
